MGX - Rasio kapitalisasi pasar marang pendapatan Metagenomi Inc.
Metagenomi, Inc. (MGX) is currently focused on developing genome editing tools, which makes its revenues dependent on grants and partners. The fluctuation in the P/S ratio illustrates the market reaction to this risk. Meanwhile, AI-driven discovery of new nucleases creates a scientific standoff within the FDA, while colossal R&D expenditures form a powerful defensive barrier. The current 3.70 metric determines the status of the sales valuation parameter.
metagenomi.co (MGX) - rincian metrik lan laporan keuangan
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Metagenomi, Inc.|MGX - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal metagenomi.co|MGX - Utang perusahaan|Utang marang nilai buku Metagenomi Therapeutics|MGX - Utang jangka dawa perusahaan|Tanggungan jangka cendhak Metagenomi|Rasio likuiditas darurat metagenomi.co
- data bathi resik lan rasio valuasi:
MGX - Bathi resik|Prakiraan bathi resik Metagenomi, Inc.|MGX - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep Metagenomi, Inc|MGX - Pangali PEG|Pangali EV/EBITDA Metagenomi|MGX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Metagenomi|MGX - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan metagenomi.co|MGX - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep Metagenomi, Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:MGX (Metagenomi)
The P/S ratio determines the market value of a business relative to its actual cash flow from sales. By analyzing the P/S ratio of a company, an investor assesses the degree of overpayment for an asset through the ratio of market capitalization to revenue. This metric measures the commercial potential of an enterprise, excluding the impact of net income. For Metagenomi, Inc. (MGX), this reflects the market's confidence in the monetization of unique microbial tool libraries and new genome editing systems.
Perusahaan pesaing
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rasio rega marang dodolan|Stoke Corp - Multiplikator P/S|BLFS (BioLife) - Rasio kapitalisasi marang pendapatan|wavelifesciences.com (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Prime Medicine Corp (PRME)|Multiplikator P/S TSHA|Multiplikator P/S uniQure N.V. (QURE)|Rasio rega marang pendapatan MeiraGTx Holdings plc MGTX|RGNX: Rasio kapitalisasi marang pendapatan|Solid Biosciences Inc - Multiplikator P/S|OCGN - Multiplikator P/S|PACB: Multiplikator P/S|BNTC - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Design Therapeutics, Inc.|RCKT: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Korro Bio, Inc. KRRO|EDIT: Rasio kapitalisasi marang pendapatan|SLN - Rasio rega marang pendapatan|Multiplikator rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Kapitalisasi marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator P/S|Rasio rega marang pendapatan Nautilus Bio|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
